7,8-dihydroxy-4-(3,4,5-trimethoxyphenyl)coumarin

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 新黄酮类化合物
• 英文名称: 7,8-dihydroxy-4-(3,4,5-trimethoxyphenyl)coumarin
• 英文别名: 7,8-Dihydroxy-4-(3,4,5-trimethoxy-phenyl)-cumarin；7,8-Dihydroxy-4-(3,4,5-trimethoxyphenyl)chromen-2-one；7,8-dihydroxy-4-(3,4,5-trimethoxyphenyl)chromen-2-one
• 化学式: C₁₈H₁₆O₇
• 分子量: 344.321
• InChiKey: AVJGHUOMLXVETQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  94.4
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  7,8-dihydroxy-4-(3,4,5-trimethoxyphenyl)coumarin 在 碘 、 氢化铝 作用下， 以 乙腈 为溶剂， 以90%的产率得到7,8-dihydroxy-4-(3,4,5-trihydroxyphenyl)coumarin
  参考文献：
  名称：

  新型新黄酮衍生物作为潜在的抗糖尿病药的合成和生物学评估†

  摘要：

  使用硫酸化的蒙脱石K-10作为催化剂合成了各种取代的新类黄酮衍生物。该方法是环境友好的，可持续的和经济的，使用丰富的地球催化剂，在分离和纯化过程中方便，副产物少，副产物少。筛选那些新类黄酮衍生物的抗氧化剂，α-葡萄糖苷酶抑制作用，醛糖还原酶2（ALR2）抑制作用和晚期糖基化终产物形成抑制作用。大多数化合物显示出显着的抗氧化剂和先进的糖基化终产物（AGE）形成抑制活性。有趣的是，在30种化合物中，8k和8l被发现比标准药物槲皮素具有更高的ALR2抑制活性。药理研究表明，具有相邻7,8-二羟基基团的新黄酮类化合物在抑制ALR2方面更有效。抗糖尿病活性研究表明，化合物8l和8m在体内与标准药物glibenclamide等效。总之，目标化合物81提供了用于开发糖尿病和糖尿病并发症的治疗剂或预防剂的潜在药物设计概念。

  DOI：

  10.1039/c7ra06457h
• 作为产物：
  描述：

  ethyl 2,3-dibromo-3-(3,4,5-trimethoxyphenyl)propionate 在 potassium hydroxide 作用下， 以 乙醇 、 硝基苯 为溶剂， 反应 5.0h， 生成 7,8-dihydroxy-4-(3,4,5-trimethoxyphenyl)coumarin
  参考文献：
  名称：

  新型新黄酮衍生物作为潜在的抗糖尿病药的合成和生物学评估†

  摘要：

  使用硫酸化的蒙脱石K-10作为催化剂合成了各种取代的新类黄酮衍生物。该方法是环境友好的，可持续的和经济的，使用丰富的地球催化剂，在分离和纯化过程中方便，副产物少，副产物少。筛选那些新类黄酮衍生物的抗氧化剂，α-葡萄糖苷酶抑制作用，醛糖还原酶2（ALR2）抑制作用和晚期糖基化终产物形成抑制作用。大多数化合物显示出显着的抗氧化剂和先进的糖基化终产物（AGE）形成抑制活性。有趣的是，在30种化合物中，8k和8l被发现比标准药物槲皮素具有更高的ALR2抑制活性。药理研究表明，具有相邻7,8-二羟基基团的新黄酮类化合物在抑制ALR2方面更有效。抗糖尿病活性研究表明，化合物8l和8m在体内与标准药物glibenclamide等效。总之，目标化合物81提供了用于开发糖尿病和糖尿病并发症的治疗剂或预防剂的潜在药物设计概念。

  DOI：

  10.1039/c7ra06457h

文献信息

• Bargellini; Grippa, Gazzetta Chimica Italiana, 1927, vol. 57, p. 141
  作者：Bargellini、Grippa

  DOI：——

  日期：——
• Antioxidant and antitumor activities of 4-arylcoumarins and 4-aryl-3,4-dihydrocoumarins
  作者：Keyun Zhang、Weixian Ding、Jie Sun、Bin Zhang、Fujiao Lu、Ren Lai、Yong Zou、Gabriel Yedid

  DOI：10.1016/j.biochi.2014.03.014

  日期：2014.12

  Five 4-arylcoumarins (1c-g) and twelve 3,4-dihydro-4-arylcoumarins (2a-l) were synthesized and tested for antioxidant activity, antitumor activity, toxicity and structure-activity relationships analysis. 4-Arylcoumarins and 3,4-dihydro-4-arylcoumarins that possess two hydroxyl groups in ortho position, such as 1d, 1f, 2a, 2f, 2g and 2h had stronger radical scavenging properties than that of vitamin C (Vit C) in ABTS(center dot+) assay. Kinetic traces of scavenging ABTS(center dot+) and DPPH radicals showed that all the reaction could reached endpoint in 1 min, which was similar with Vit C. 4-Arylcoumarins with 3'-hydroxyl-4'-methylphenyl structural show more efficient NO center dot radical scavenging activity. Three compounds 2e, 1f and 2a, in particular had superior EC50 for NO center dot scavenging than did Vit C. MTT assay indicated that one compound in particular had a potential antitumor effect, inhibiting proliferation of BGC-823 cells and almost completely killing them at a concentration 62.5 mg/L. With same concentration 100 mu g/mL, hemolytic analysis in rabbit red blood cells showed that only two compounds had hemolytic activity with a little more than 5% hemolysis. Injection and oral toxicity tests on Galleria mellonella larvae showed that none of the tested 4-arylcoumarins significantly affected their appetite, viability and mortality. (C) 2014 Elsevier B.V. and Societe francaise de biochimie et biologie Moleculaire (SFBBM). All rights reserved.
• Synthesis and biological evaluation of 4-arylcoumarins as potential anti-Alzheimer’s disease agents
  作者：Yinling Yun、Jie Yang、Yuhang Miao、Xiaojing Wang、Jie Sun

  DOI：10.1016/j.bmcl.2019.126900

  日期：2020.2

  Alzheimer's disease (AD) is a progressive neurological degenerative disease that has complex pathogenesis. A variety of studies in humans indicate that several enzymes inhibitors can be useful in the treatment of AD, including acetylcholinesterase (AchE), butyrylcholinesterase (BuChE) and monoamine oxidase (MAO). Various substituted 4-arylcoumarin derivatives were synthesised, and their activity in vitro were investigated, including AChE/BuChE inhibitory activity, MAO inhibitory activity, and antioxidant activity. Most of the compounds were found to exhibit high inhibitory activity, and individual compounds have extremely excellent activities. Therefore 4-arylcoumarins provides an idea for drugs design for the development of therapeutic or preventive agents for AD.